Press releases and featured news articles.
Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, announced today the appointment of Robert (“Robbie”) L. Huffines as an independent director effective December 1, 2023.
HAYWARD, Calif. – September 11, 2023 – Eikon Therapeutics, Inc., which advances breakthrough therapeutics through the purposeful integration of engineering and science, announced today that it has completed the previously announced integration of TLR 7 and 8 co-agonists into its clinical development program, and that it expects to discuss the further development of these molecules with the U.S. Food and Drug Administration (FDA) in the fourth quarter.
HAYWARD, Calif. - June 1, 2023 - Eikon Therapeutics, Inc., a clinical stage biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced its Clinical Development organization. Under the leadership of Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon, this team of experienced industry professionals will be responsible for every stage of clinical development and accelerating the company’s lead pipeline candidates into and through trials and regulatory review. Eikon recently announced its development pipeline, which includes a number of acquired clinical and preclinical stage assets that complement its discovery-stage programs. “In support of our vision to build a global biotechnology company focused on developing important new medicines, we have recruited a sophisticated team of industry experts who have decades of collective experience in managing every component of advancing new drug candidates from their earliest stages through the clinic to regulatory approval,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. “This team is fully integrated within our organization and is working alongside our advanced engineering and research team, who have dramatically accelerated the performance of our pioneering Single Molecule Tracking (SMT) technology. Together, they position Eikon to become a fully integrated global biotechnology company.”
HAYWARD, Calif. – June 1, 2023 – Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has acquired exclusive rights to multiple early- to mid-stage assets, leveraging its proprietary Single Molecule Tracking (SMT) technology to drive strategic decisions around its new drug pipeline. Eikon successfully completed three transactions, including the acquisition of global rights to develop and commercialize clinical-stage Toll-like receptor 7 and 8 (TLR7/8) agonist immune modulators from Seven and Eight Biotherapeutics Corp. that have been tested in over 150 patients with advanced, refractory, solid tumors. These immune modulators have shown tolerable safety and activity both as monotherapy and in combination with PD-(L)1 inhibitors.
(Hayward, Calif. March 28, 2023) Today, Eikon Therapeutics officially opened its second location in Hayward, expanding the company’s footprint to scale its research and engineering infrastructure. Eikon is a biotechnology company that is transforming the advancement of breakthrough therapeutics through the purposeful integration of engineering and science.
Liam Elliott, Nick Ha, Jaclyn Ho, Aaron Klammer, Steve Basham, Daniel Anderson, Russ Berman, Mason Bretan, Amine Driouchi
HAYWARD, Calif. & NEW YORK--(BUSINESS WIRE)--Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a lease with Alexandria Real Estate Equities, Inc. for its new East Coast base of operations located in the Alexandria Center® for Life Science in New York City.
HAYWARD, Calif. – June 16, 2022 – Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters. Eikon’s new headquarters will consist of approximately 285,000 square feet of office and laboratory space on a new life sciences campus being developed by Alexandria in Millbrae, California.
HAYWARD, Calif.--( BUSINESS WIRE)--Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022. Ms. Washington is among the most experienced business leaders in the biopharmaceutical and technology industries, having served as Chief Financial Officer at Gilead, Inc. from 2008 until 2019, managing global finance, investor relations, facilities and operations, and information technology during a period when corporate revenue grew by more than six-fold.
HAYWARD, CALIF – March 30, 2022 – Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022. Among the world’s most admired global business leaders, Mr. Frazier is the executive chairman and former CEO of Merck (NYSE:MRK), chairman of health assurance initiatives at the venture capital firm General Catalyst, and a director of Exxon Mobil Corporation (NYSE:XOM).
HAYWARD, Calif.--( BUSINESS WIRE)--Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in July.
HAYWARD, Calif. – January 6, 2022 – Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to drug discovery, today announced that it has closed a $517.8 million Series B financing. Since its founding two years ago, Eikon Therapeutics has raised more than $668 million to advance its mission of inventing new therapies that address grievous illness.
Helen Liu, Lakshmi Akella, Hanzhe Chen, Eric Gonzalez, Adi Hanuka, Alec Heckert, Jaclyn Ho, Yan Li, Akshay Sule, Sarah Pierce, Ruensern Tan, Daniel Anderson, Hilary P. Beck, David McSwiggen
Eikon is now being led by one of the drug industry's most accomplished R&D leaders: Roger Perlmutter, who left the drug-making giant Merck to become CEO of Eikon in May 2021.
David T. McSwiggen, Yangzhong Tang, Sebastia Agramunt, Caitlyn Bonilla, Mason Bretan, Hanzhe Chen, Brianna Conroy, Amine Driouchi, Eric Gonzalez, Matthew Guthrie, Alec Heckert, Michael Hirte, Jaclyn Ho, Fedor Ilkov, Stephanie Johnson, Reed Kelso, Aaron Klammer, Yan Li, Kevin Lin, Helen Liu, Brian Margolin, Patrick McNamara, Laurence Meyer, Greg Snyder, Jordan Toutounchian, Martin Vana, Russ Berman, Daniel J. Anderson, Hilary P. Beck
These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma.
HAYWARD, Calif. (BUSINESS WIRE) Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has named Alfred “Freddie” Bowie, Jr, PhD, to the newly created position of Chief Financial Officer. In this role, Dr. Bowie will have broad responsibility for finance, operational functions, and business development.
Roger Perlmutter, M.D., Ph.D., has taken up the CEO post at Eikon Therapeutics. The startup disclosed the hiring of the former president of Merck Research Laboratories alongside news that it has raised a $148 million series A round to apply live-cell super-resolution microscopy to drug discovery.
HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. The company also announced the appointment of Roger M. Perlmutter, MD, PhD, as its new Chief Executive Officer.
Articles about Eikon Therapeutics.
Articles about Eikon Therapeutics.
Eikon is now being led by one of the drug industry's most accomplished R&D leaders: Roger Perlmutter, who left the drug-making giant Merck to become CEO of Eikon in May 2021.
These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma.
Roger Perlmutter, M.D., Ph.D., has taken up the CEO post at Eikon Therapeutics. The startup disclosed the hiring of the former president of Merck Research Laboratories alongside news that it has raised a $148 million series A round to apply live-cell super-resolution microscopy to drug discovery.
Articles about Eikon Therapeutics.
Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, announced today the appointment of Robert (“Robbie”) L. Huffines as an independent director effective December 1, 2023.
HAYWARD, Calif. – September 11, 2023 – Eikon Therapeutics, Inc., which advances breakthrough therapeutics through the purposeful integration of engineering and science, announced today that it has completed the previously announced integration of TLR 7 and 8 co-agonists into its clinical development program, and that it expects to discuss the further development of these molecules with the U.S. Food and Drug Administration (FDA) in the fourth quarter.
HAYWARD, Calif. - June 1, 2023 - Eikon Therapeutics, Inc., a clinical stage biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced its Clinical Development organization. Under the leadership of Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon, this team of experienced industry professionals will be responsible for every stage of clinical development and accelerating the company’s lead pipeline candidates into and through trials and regulatory review. Eikon recently announced its development pipeline, which includes a number of acquired clinical and preclinical stage assets that complement its discovery-stage programs. “In support of our vision to build a global biotechnology company focused on developing important new medicines, we have recruited a sophisticated team of industry experts who have decades of collective experience in managing every component of advancing new drug candidates from their earliest stages through the clinic to regulatory approval,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. “This team is fully integrated within our organization and is working alongside our advanced engineering and research team, who have dramatically accelerated the performance of our pioneering Single Molecule Tracking (SMT) technology. Together, they position Eikon to become a fully integrated global biotechnology company.”
HAYWARD, Calif. – June 1, 2023 – Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has acquired exclusive rights to multiple early- to mid-stage assets, leveraging its proprietary Single Molecule Tracking (SMT) technology to drive strategic decisions around its new drug pipeline. Eikon successfully completed three transactions, including the acquisition of global rights to develop and commercialize clinical-stage Toll-like receptor 7 and 8 (TLR7/8) agonist immune modulators from Seven and Eight Biotherapeutics Corp. that have been tested in over 150 patients with advanced, refractory, solid tumors. These immune modulators have shown tolerable safety and activity both as monotherapy and in combination with PD-(L)1 inhibitors.
(Hayward, Calif. March 28, 2023) Today, Eikon Therapeutics officially opened its second location in Hayward, expanding the company’s footprint to scale its research and engineering infrastructure. Eikon is a biotechnology company that is transforming the advancement of breakthrough therapeutics through the purposeful integration of engineering and science.
HAYWARD, Calif. & NEW YORK--(BUSINESS WIRE)--Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a lease with Alexandria Real Estate Equities, Inc. for its new East Coast base of operations located in the Alexandria Center® for Life Science in New York City.
HAYWARD, Calif. – June 16, 2022 – Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters. Eikon’s new headquarters will consist of approximately 285,000 square feet of office and laboratory space on a new life sciences campus being developed by Alexandria in Millbrae, California.
HAYWARD, Calif.--( BUSINESS WIRE)--Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022. Ms. Washington is among the most experienced business leaders in the biopharmaceutical and technology industries, having served as Chief Financial Officer at Gilead, Inc. from 2008 until 2019, managing global finance, investor relations, facilities and operations, and information technology during a period when corporate revenue grew by more than six-fold.
HAYWARD, CALIF – March 30, 2022 – Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022. Among the world’s most admired global business leaders, Mr. Frazier is the executive chairman and former CEO of Merck (NYSE:MRK), chairman of health assurance initiatives at the venture capital firm General Catalyst, and a director of Exxon Mobil Corporation (NYSE:XOM).
HAYWARD, Calif.--( BUSINESS WIRE)--Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in July.
HAYWARD, Calif. – January 6, 2022 – Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to drug discovery, today announced that it has closed a $517.8 million Series B financing. Since its founding two years ago, Eikon Therapeutics has raised more than $668 million to advance its mission of inventing new therapies that address grievous illness.
HAYWARD, Calif. (BUSINESS WIRE) Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has named Alfred “Freddie” Bowie, Jr, PhD, to the newly created position of Chief Financial Officer. In this role, Dr. Bowie will have broad responsibility for finance, operational functions, and business development.
HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. The company also announced the appointment of Roger M. Perlmutter, MD, PhD, as its new Chief Executive Officer.
Articles about Eikon Therapeutics.
Biophysical Society Annual Meeting (BPS) 2023
Liam Elliott, Nick Ha, Jaclyn Ho, Aaron Klammer, Steve Basham, Daniel Anderson, Russ Berman, Mason Bretan, Amine Driouchi
Biophysical Society Annual Meeting (BPS) 2023
William Forrest, Jaclyn Ho, Aaron Klammer, Steve Basham, Russ Berman, Daniel Anderson, Mason Bretan, Amine Driouchi
Biophysical Society Annual Meeting (BPS) 2023
Liam Elliott, Nick Ha, Jaclyn Ho, Aaron Klammer, Steve Basham, Daniel Anderson, Russ Berman, Mason Bretan, Amine Driouchi
Cold Harbor Spring Laboratory (CHSL) Meeting on Single Biomolecules 2022
Helen Liu, Lakshmi Akella, Hanzhe Chen, Eric Gonzalez, Adi Hanuka, Alec Heckert, Jaclyn Ho, Yan Li, Akshay Sule, Sarah Pierce, Ruensern Tan, Daniel Anderson, Hilary P. Beck, David McSwiggen
Medicinal Chemistry Gordon Research Conference (GRC) 2021
David T. McSwiggen, Yangzhong Tang, Sebastia Agramunt, Caitlyn Bonilla, Mason Bretan, Hanzhe Chen, Brianna Conroy, Amine Driouchi, Eric Gonzalez, Matthew Guthrie, Alec Heckert, Michael Hirte, Jaclyn Ho, Fedor Ilkov, Stephanie Johnson, Reed Kelso, Aaron Klammer, Yan Li, Kevin Lin, Helen Liu, Brian Margolin, Patrick McNamara, Laurence Meyer, Greg Snyder, Jordan Toutounchian, Martin Vana, Russ Berman, Daniel J. Anderson, Hilary P. Beck
